A phase II study of tasisulam sodium (LY573636) as second-line treatment for patients with unresectable or metastatic melanoma. Background: Recurrence will occur in about 20% of all primary melanoma ...
Ferring’s Rebyota, a novel first-in-class microbiota-based live biotherapeutic, has been approved by the FDA for the prevention of recurrence of Clostridioides difficile infection (CDI) in individuals ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback